Ovarian Cancer

Latest News

Female Asian patient at doctor | Image Credit: DragonImages - stock.adobe.com
Ovarian Cancer Survival Varies Widely Among Asian American Subgroups

November 13th 2024

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the importance of analyzing these groups separately.

HPV written in blocks | Image Credit: Iana Alter - stock.adobe.com
HPV 16 and 18 Linked to Ovarian Cancer Risk

October 29th 2024

Balanced diet | Image Credit: nadianb - stock.adobe.com
Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer

October 24th 2024

Patient with ovarian cancer | Image Credit: Kiattisak - stock.adobe.com
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer

October 22nd 2024

Air pollution | Image Credit: hramovnick - stock.adobe.com
Increased Ovarian Cancer Risk Linked to Elevated Nitrogen Dioxide Exposure, Study Finds

October 18th 2024

Ovarian Cancer Guideline Updates 2024

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

More News

Ovarian cancer text with medications | tashatuvango - stock.adobe.com
June 23rd 2023

FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer

Russ Conroy
Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.
MIRASOL: Mirvetuximab Soravtansine Improves PFS, OS in Certain Women With Recurrent Ovarian Cancer
June 4th 2023

MIRASOL: Mirvetuximab Soravtansine Improves PFS, OS in Certain Women With Recurrent Ovarian Cancer

Mary Caffrey
The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy.
ELAHERE logo
April 26th 2023

SORAYA Data Shed Light on Responses to Mirvetuximab Soravtansine Based on Prior Bevacizumab Exposure

AJMC Staff
The antibody drug conjugate received FDA approval in November 2022.
Neil Iyengar, MD
February 21st 2023

Neil Iyengar, MD, Emphasizes Importance of Population Health Lens in Oncology

Hayden E. Klein
FDA Approves Mirvetuximab Soravtansine-gynx for Platinum-Resistant Ovarian Cancer
November 15th 2022

FDA Approves Mirvetuximab Soravtansine-gynx for Platinum-Resistant Ovarian Cancer

Laura Joszt, MA
In addition to the drug approval, the FDA approved a companion diagnostic to be used to identify patients who are eligible to receive the treatment.
Ovarian cancer graphic
February 15th 2021

Proximity to Treatment, Racial Disparities Are Seen in Ovarian Cancer Survival

Maggie L. Shaw
Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.
Doctor-patient consult
February 11th 2021

Choice of Ovarian Cancer Surgery Influenced by Risk Perception

Maggie L. Shaw
An investigation of 24 women from the United Kingdom’s PROTECTOR trial has revealed that their concerns toward cancer risk and menopause affect their choice of surgery as treatment for ovarian cancer.
Laparoscopy Shown to Be Cost-effective in Evaluating Newly Diagnosed Ovarian Cancer
February 5th 2021

Laparoscopy Shown to Be Cost-effective in Evaluating Newly Diagnosed Ovarian Cancer

AJMC Staff
Researchers from MD Anderson Cancer Center found that laparoscopy cost more upfront but eliminated wasteful treatment decisions.
Recent Adavosertib Results in Ovarian Cancer Could Be Sign of Things to Come
January 30th 2021

Recent Adavosertib Results in Ovarian Cancer Could Be Sign of Things to Come

Mary Caffrey
Recent results with adavosertib in ovarian cancer could signal future positive results, given the number of trials using the targeted therapy with the PARP inhibitor olaparib.
Site Logo
January 20th 2021

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

Mary Caffrey
Lauren M. Corduck, who turned a diagnosis of ovarian cancer into a crusade to educate others with similar genetic mutations, died on December 24, 2020. She was 49.
Older Patient Consulting With Doctor
January 15th 2021

Aggressive Treatment Might Benefit Older Patients With Ovarian Cancer

Rose McNulty
Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.
Jessica Greenwood, MS
January 15th 2021

Payer Coverage Is the Key to Cost-effective Panel Testing in Gynecological Cancers

Mary Caffrey
Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company.
Daniel F. Hayes, MD
January 9th 2021

What Is Clinical Utility in a Tumor Biomarker Test? Former ASCO President Knows It When He Sees It

Mary Caffrey
Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.
women pain
January 9th 2021

Study Finds Link Between Larger Endometriomas and Ovarian Cancer

AJMC Staff
A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.
Bradley Monk, MD, FACOG, FACS
December 18th 2020

Dr Bradley Monk Discusses PARP Inhibitor Reimbursement

Rose McNulty
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.
Ovarian Cancer
December 11th 2020

Novel Combination Shows Promise in Recurrent Ovarian Cancer

Rose McNulty
A combination of pembrolizumab with bevacizumab and cyclophosphamide showed clinical activity and tolerability in patients with recurrent ovarian cancer, a small study found.
Teal ovarian cancer awareness ribbon
December 10th 2020

Top-line Phase 1 Results for Cantrixil Confirm Earlier Efficacy, Safety Signals

AJMC Staff
Kazia Therapeutics will report the full results at a future scientific meeting.
Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results
December 5th 2020

Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results

AJMC Staff
One patient had a complete response and the majority of patients achieved disease control at 12 weeks.
Discussion of Ovarian Cancer Risk
December 4th 2020

Assisted Reproductive Technology Does Not Increase Ovarian Cancer Risk

Rose McNulty
New findings in Journal of the National Cancer Institute contradict previous research indicating that assisted reproductive technology might lead to an increased risk of ovarian cancer.
Study Examines Impact of Tumor Mutational Burden on Ovarian Cancer
November 25th 2020

Study Examines Impact of Tumor Mutational Burden on Ovarian Cancer

Allison Inserro
Tumor mutational burden is an emerging biomarker to predict response to immune checkpoint inhibitors, but its utility as a prognostic indicator in ovarian cancer is unclear.
Small Study Finds Potential Risk of Hematologic Abnormalities After Ovarian Cancer Treatment
November 24th 2020

Small Study Finds Potential Risk of Hematologic Abnormalities After Ovarian Cancer Treatment

Jared Kaltwasser
The new report suggests that patients treated with prolonged poly-ADP-ribose polymerase inhibitors after chemotherapy may need close hematological monitoring.
Patients With Ovarian Cancer Struggle With Uncertainty, Fears of Future, Study Finds
November 23rd 2020

Patients With Ovarian Cancer Struggle With Uncertainty, Fears of Future, Study Finds

Jared Kaltwasser
The dearth of effective treatment options for patients with ovarian cancer not only leads to poor health outcomes, but also leads to psychological distress, according to new research.
Ovarian tumor graphic
November 19th 2020

Review Offers First Head-to-Head Look at PARP Inhibitors for Ovarian Cancer

Jaime Rosenberg
Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.
Careful Observation of Ovarian Cysts Safe Alternative to Surgery
February 9th 2019

Careful Observation of Ovarian Cysts Safe Alternative to Surgery

Samantha DiGrande
Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
Dr John Schorge Discusses Prevention Methods in Ovarian Cancer
June 30th 2018

Dr John Schorge Discusses Prevention Methods in Ovarian Cancer

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses different prevention methods in ovarian cancer.
Site Logo
August 18th 2017

Expanded Approval, New Dosage Form for Olaparib in Recurrent Ovarian Cancer

Surabhi Dangi-Garimella, PhD
A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo